EP Patent

EP1298125A1 — Substituted benzimidazole compounds and their use for the treatment of cancer

Assigned to Aventis Pharma SA · Expires 2003-04-02 · 23y expired

What this patent protects

New benzimidazole compounds of formula (I) and their use as cyclin-dependent kinases inhibitors compounds as well as new pharmaceutical compositions containing them. <CHEM>

USPTO Abstract

New benzimidazole compounds of formula (I) and their use as cyclin-dependent kinases inhibitors compounds as well as new pharmaceutical compositions containing them. <CHEM>

Drugs covered by this patent

Patent Metadata

Patent number
EP1298125A1
Jurisdiction
EP
Classification
—
Expires
2003-04-02
Drug substance claim
No
Drug product claim
No
Assignee
Aventis Pharma SA
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.